Drug candidates from our molecular platforms normalize the immune system by downregulating pro-inflammatory immune response and upregulating regulatory immune response.
IMD-Pharma S.A.S is a french biotechnology company conducting research and development of innovative drug candidates for immune-related inflammatory diseases.
Founded in 2016, IMD-Pharma is a company from the Laboratoire de Chimie de Coordination (CNRS) and the Centre de Physiopathologie de Toulouse Purpan (INSERM/CNRS/Université Toulouse III).
Company Details
- Employees
- 6
- Founded
- -
- Address
- Toulouse, Fr
- Industry
- Biotechnology
- Website
- imd-pharma.com
- Keywords
- immuno-modulation, anti-inflammatory drugs, chronic inflammatory diseases, Multiple Sclerosis, Rheumatoid Arthritis, dendrimers, monocyte rehabilitation, psoriasis.
- HQ
- Toulouse
- Competitors
- Cell-Easy, Vaiomer, Dendris, ANTABIO, SYNAXYS, IMACTIV-3D, TWB, AFFICHEM, Imavita, ENEAPHARM.
Imd-Pharma Sas Questions
Imd-Pharma Sas's website is imd-pharma.com
Imd-Pharma Sas's LinkedIn profile is https://fr.linkedin.com/company/imd-pharma-sas
Imd-Pharma Sas has
6 employees.
View email and phone details for 6
employees at Imd-Pharma Sas.
Imd-Pharma Sas's industry is
Biotechnology
Imd-Pharma Sas's categories are Biotechnology
Imd-Pharma Sas's founding year is 2016
